PCSK9 and neoplasm: The use of cholesterol-lowering drugs (e.g., statins, PCSK9 inhibitors) may play a role in tumor immunotherapy by promoting the conversion of cold tumors to hot tumors, enhancing CD8+ T cell activity, and reducing PD-L1 expression in cancer cells, thus inhibiting tumor progression (58–62).